Shell Asset Management Co. Sells 1,809 Shares of Xencor, Inc. (NASDAQ:XNCR)

Shell Asset Management Co. decreased its position in shares of Xencor, Inc. (NASDAQ:XNCRGet Rating) by 12.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,236 shares of the biopharmaceutical company’s stock after selling 1,809 shares during the quarter. Shell Asset Management Co.’s holdings in Xencor were worth $326,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. bought a new stake in shares of Xencor during the first quarter valued at approximately $3,885,000. Charles Schwab Investment Management Inc. grew its holdings in Xencor by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 442,965 shares of the biopharmaceutical company’s stock worth $17,772,000 after buying an additional 7,778 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in Xencor by 4.9% during the fourth quarter. Segall Bryant & Hamill LLC now owns 98,213 shares of the biopharmaceutical company’s stock worth $3,941,000 after buying an additional 4,557 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in Xencor during the fourth quarter worth $560,000. Finally, Sofinnova Investments Inc. bought a new stake in Xencor during the fourth quarter worth $21,546,000. Institutional investors own 98.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on XNCR shares. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a report on Thursday. Canaccord Genuity Group restated a “buy” rating and issued a $50.00 price objective on shares of Xencor in a research note on Wednesday, July 6th. Finally, Piper Sandler reduced their price objective on Xencor from $66.00 to $42.00 and set an “overweight” rating for the company in a research note on Monday, May 23rd. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.83.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $29.34 on Friday. Xencor, Inc. has a one year low of $19.35 and a one year high of $43.61. The business’s fifty day moving average price is $26.74 and its 200-day moving average price is $27.94. The stock has a market capitalization of $1.75 billion, a PE ratio of 86.30 and a beta of 0.61.

Xencor (NASDAQ:XNCRGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $1.09. Xencor had a return on equity of 3.19% and a net margin of 7.77%. The firm had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $26.17 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. The business’s revenue for the quarter was up 152.2% compared to the same quarter last year. As a group, equities analysts expect that Xencor, Inc. will post -1.62 EPS for the current fiscal year.

About Xencor

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Articles

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCRGet Rating).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.